[HTML][HTML] Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial

…, SK Rai, C Singh, SV Redkar, CS Gillurkar… - The Lancet Infectious …, 2021 - thelancet.com
Background To mitigate the effects of COVID-19, a vaccine is urgently needed. BBV152 is a
whole-virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist …

[HTML][HTML] Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3 …

…, S Verma, C Singh, SV Redkar, CS Gillurkar… - The Lancet Infectious …, 2021 - thelancet.com
Background BBV152 is a whole-virion inactivated SARS-CoV-2 vaccine (3 μg or 6 μg)
formulated with a toll-like receptor 7/8 agonist molecule (IMDG) adsorbed to alum (Algel). We …

[HTML][HTML] Persistence of immunity and impact of third dose of inactivated COVID-19 vaccine against emerging variants

…, S Verma, C Singh, SV Redkar, CS Gillurkar… - Scientific reports, 2022 - nature.com
This is a comprehensive report on immunogenicity of COVAXIN ® booster dose against
ancestral and Variants of Concern (VOCs) up to 12 months. It is well known that neutralizing …

Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of …

…, P Reddy, S Verma, C Singh, SV Redkar, CS Gillurkar… - medRxiv, 2020 - medrxiv.org
Background BBV152 is a whole-virion inactivated SARS-CoV-2 vaccine (3 µg or 6 µg)
formulated with a Toll-like receptor 7/8 agonist molecule adsorbed to alum (Algel-IMDG). Earlier, …

A phase 1: safety and immunogenicity trial of an inactivated SARS-CoV-2 vaccine-BBV152

…, S Verma, SK Rai, C Singh, SV Redkar, CS Gillurkar… - MedRxiv, 2020 - medrxiv.org
Background BBV152 is a whole-virion inactivated SARS-CoV-2 vaccine formulated with a
TLR 7/8 agonist molecule adsorbed to alum (Algel-IMDG). Methods We conducted a double-…

Persistence of immunity and impact of a third (booster) dose of an inactivated SARS-CoV-2 vaccine, BBV152; a phase 2, double-blind, randomised controlled trial

…, P Reddy, S Verma, C Singh, SV Redkar, CS Gillurkar… - MedRxiv, 2022 - medrxiv.org
Background Neutralising antibody responses to SARS-CoV-2 vaccines have been reported
to decline within 6 months of vaccination, particularly against Variants of Concern (VOC). We …

Safety and immunogenicity trial of an inactivated SARS-CoV-2 vaccine-BBV152: A phase 1, double-blind, randomised control trial

…, SV Attri, SK Rai, C Singh, SV Redkar, CS Gillurkar… - 2020 - papers.ssrn.com
Background: BBV152 is a whole-virion inactivated SARS-CoV-2 vaccine (3 μg or 6 μg)
formulated with a Toll-Like Receptor 7/8 agonist molecule adsorbed to alum (Algel-IMDG) or 6 μg …

Transfer Learning with MotifTransformers for Predicting Protein-Protein Interactions Between a Novel Virus and Humans (preprint)

…, M Tambe, M Marathe, S Redkar, CS Gillurkar… - 2020 - pesquisa.bvsalud.org
The novel coronavirus SARS-CoV-2, which causes Coronavirus disease 2019 (COVID19),
is a significant threat to worldwide public health. Viruses such as SARS-CoV-2 infect the …

Rapid SARS-CoV-2 Detection and Classification Using Phase Imaging with Computational Specificity (preprint)

…, M Tambe, M Marathe, S Redkar, CS Gillurkar… - 2020 - pesquisa.bvsalud.org
Efforts to mitigate the COVID-19 crisis revealed that fast, accurate, and scalable testing is
crucial for curbing the current impact and that of future pandemics. We propose an optical …

[PDF][PDF] COVID19 vaccine: COVAXIN®-India's first indigenous effective weapon to fight against coronavirus (A Review)

S Darbar, S Agarwal, S Saha - Parana J Sci Educ, 2021 - researchgate.net
Since the pandemic began (COVID19), India has confirmed more than 11 million cases and
over 157,000 deaths. The country has recorded the second-highest number of Covid-19 …
Did you mean to search for: Chandrashekhar Gillurkar